SCHEMBL21151025

SCHEMBL21151025

C1#Cc2ccccc2Nc2ccccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 5/20 0.43
MAPT P10636 5/20 0.43
NOX1 Q9Y5S8 5/20 0.42
BCHE P06276 4/20 0.42
ACHE P22303 4/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
CYP3A4 P08684 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
MAOA P21397 2/20 0.42
ALOX5 P09917 1/20 0.42
CYP1A2 P05177 1/20 0.42
POLB P06746 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
ALOX15 P16050 1/20 0.42
ALOX12 P18054 1/20 0.42
CNR1 P21554 1/20 0.42
PTGS1 P23219 1/20 0.42
SLC6A2 P23975 1/20 0.42
HTR2C P28335 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL577541 0.82 GAA (0.43) GAAMAPTNOX1BCHEACHE
SCHEMBL577542 0.82 GAA (0.43) GAAMAPTNOX1BCHEACHE
SCHEMBL19543486 0.78 ALDH1A1 (0.32) MEN1KMT2ACYP3A4TDP1MAOA
SCHEMBL12319785 0.78 LRRK2 (0.55) GAAMAPTMAOACYP1A2ALOX15
SCHEMBL237481 0.73
SCHEMBL29767688 0.73 CYP2A6 (0.36) MAPTACHECYP3A4TDP1POLB
SCHEMBL9148625 0.73 CYP2A6 (0.36) MAPTACHECYP3A4TDP1POLB
SCHEMBL624418 0.73 GAA (0.59) GAAMAPTNOX1BCHEACHE
SCHEMBL29369547 0.73 GAA (0.59) GAAMAPTNOX1BCHEACHE
SCHEMBL76607 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399356-A1 ANTIBODY DRUG CONJUGATES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-12-14 US disclosed
US-11725024-B2 Antibody drug conjugates TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-08-15 US disclosed
WO-2023023659-A1 NECTIN-4 ANTIBODIES AND CONJUGATES Tallac Therapeutics, Inc. (US) 2023-02-23 WO disclosed
EP-3183007-B1 PROTEIN/OLIGONUCLEOTIDE CORE-SHELL NANOPARTICLE THERAPEUTICS UNIV NORTHWESTERN (US) 2020-06-17 EP disclosed
WO-2019136442-A1 CD16A BINDING AGENTS AND USES THEREOF KLEO PHARMACEUTICALS, INC. (US) 2019-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399356-A1 ANTIBODY DRUG CONJUGATES STING1, CGAS, TBK1 GAA 335/4885MAPT 3123/4885NOX1 3067/4885
US-11725024-B2 Antibody drug conjugates STING1, CGAS, TBK1 GAA 335/4885MAPT 3123/4885NOX1 3067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.